Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Results of the votes of the Combined Shareholders' General Meeting of June 20…
Daix (France), Long Island City (New York, United States), on June 21, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined...
Nasdaq GlobeNewswire
21/06/2024
BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in…
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST –BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces that it has signed a new subscription agreement for a maximum EUR 2.1 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15").GTO…
Nasdaq GlobeNewswire
21/06/2024
Empty Capsules Market: USD 4.2B by 2029, 6.3% CAGR, Driven by Nutraceuticals &…
Browse in-depth TOC on "Empty Capsules Market" Browse in-depth TOC on "Empty Capsules Market" 356 - Tables48 - Figures333 - Pages Empty Capsules Market Report Highlights: Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=218018190 Market Projection and Growth Drivers The empty capsules market is projected to grow fromUSD 3.1 billionin 2024 toUSD 4.2 billionby 2029, at a CAGR of 6.3%. This growth is driven by...
PR Newswire
21/06/2024
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
Vivoryon Therapeutics N.V. Reports Outcomeof 2024 Annual General MeetingHalle (Saale) / Munich, Germany, June 21, 2024– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon, or the Company ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items...
Nasdaq GlobeNewswire
21/06/2024
At the SIRM Congress 2024 in Milan, ESAOTE presents the brand-new MyLab™E80, an…
Another step forward in terms of innovation, MyLab™E80 is the first ultrasound system in Esaote's brand-new E series. The 'E' stands for Expertise, referring to a series of devices designed for professionals who deal with more complex clinical cases, where diagnostic certainty and clinical efficiency play a decisive role. Another step forward in terms of innovation,MyLab™E80is the first ultrasound system in Esaote's brand-new E series. The 'E' stands for Expertise, referring to a series...
PR Newswire
21/06/2024
Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®…
As a symbol of scientific rigor, excellence, and innovation, the "Prix Galien International" awards remarkable recent health innovations available to the public, following an evaluation done by an independent committee of experts. Today this prize exists in fifteen countries, its reputation and influence have made it the most prestigious distinction in the medical field. Through this prize, the jury honors EBVALLO®, thanks to its innovative manufacturing process and mechanism of…
PR Newswire
21/06/2024
Dyspareunia Treatment Market to Hit $1,035.4 million by 2031, at a CAGR of 4.6%…
Market Dynamics: Market Dynamics : The growth of the dyspareunia treatment market is majorly driven by the increasing research and development activities for developing novel therapies to treat dyspareunia. For instance, inAugust 2019, researchers from University ofFlorence,Florence, Italytested the use of fractional carbon dioxide laser therapy for the treatment of provoked vestibulodynia, which is a form of dyspareunia. The results showed that carbon dioxide laser therapy...
PR Newswire
21/06/2024
Trading by management and close relations of management
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.June 21, 2024Company announcement No. 23 1. Details of the person discharging managerial responsibilities/person closely associated...
Nasdaq GlobeNewswire
21/06/2024
Major shareholder announcement
June 21, 2024 Company announcement No. 22Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novonesis, that as of yesterday, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 A-shares (nominally DKK 107,487,200) and 65,672,555 B-shares (nominally DKK 131,345,110) corresponding to...
Nasdaq GlobeNewswire
21/06/2024
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs…
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive CommitteeParis, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France's President, has been named Executive Vice President, Global Head of Corporate Affairs. Audrey will become a member of Sanofi's Executive Committee, reporting into CEO Paul Hudson, and will be based in Paris. Her appointment is effective July 1, 2024.In her new role, Audrey will be...
Nasdaq GlobeNewswire
21/06/2024
Molecular Pharming Market in the North America is Expected to Register the…
Download Free Sample and ToC of the Report:https://www.insightaceanalytic.com/request-sample/1712 Download Free Sample and ToC of the Report:https://www.insightaceanalytic.com/request-sample/1712 Molecular pharming refers to biologics production in plant systems to reduce the cost of microbial systems. Molecular farming is an innovative method for producing molecular medicines, including plasma proteins, enzymes, growth factors, vaccinations, and recombinant antibodies. These medicines...
PR Newswire
21/06/2024
RECKITT'S FIRST GENAI RESULTS DEMONSTRATE CHANGING FACE OF MARKETING DURING…
Beaulieu said: "As expected, GenAI was the most talked-about topic at Cannes - from the formal Festival programme, to fringe events and discussions with partners along the Croisette. As the festival draws to a close, we are proud to share the results of these pilots, as we move to scaling up." Beaulieu said : "As expected, GenAI was the most talked-about topic atCannes- from the formal Festival programme, to fringe events and discussions with partners along the Croisette. As the…
PR Newswire
21/06/2024
Targeted Protein Degradation Market PROTAC Segment is Expected to Highest Growth…
Targeted protein degradation (TPD) seeks to completely remove specific proteins from the cell, rather than merely inhibiting their activity. This approach can potentially provide more effective and sustained treatment outcomes for various diseases by thoroughly eliminating disease-causing proteins. By leveraging the cell's natural degradation pathways, TPD can address issues that traditional therapies cannot, such as drug resistance and incomplete inhibition. Consequently, this innovative…
PR Newswire
21/06/2024
Non-Viral Transfection Reagents Market worth USD 1,157.5 Million to 2031 -…
Transfection, vital for introducing nucleic acids into cells, relies historically on viral vectors but increasingly on non-viral transfection reagents. These chemicals, devoid of viral components, are pivotal in gene therapy, cell-based therapies, and vaccine development due to their safety, ease of use, and adaptability. Transfection, vital for introducing nucleic acids into cells, relies historically on viral vectors but increasingly on non-viral transfection reagents. These chemicals…
PR Newswire
21/06/2024
ISTH announces launch of new global education initiative in factor XI/XIa…
In early 2023, the ISTH organized the multi-disciplinary, international Factor XI/XIa Educational Steering Committee, a group of world-renowned experts led by Jeff Weitz, MD, to survey a sample of the multi-disciplinary target audiences for this education. In early 2023, the ISTH organized the multi-disciplinary, international Factor XI/XIa Educational Steering Committee, a group of world-renowned experts led byJeff Weitz, MD, to survey a sample of the multi-disciplinary target audiences for...
PR Newswire
21/06/2024
Weight Loss Drugs: A Game Changer in the Fight Against Obesity - New InsightAce…
Download Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2526 Download Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2526 Weight loss drugs work through various mechanisms in the body to promote weight loss, such as reducing appetite, increasing feelings of fullness, decreasing absorption of nutrients, or increasing calorie expenditure. The weight loss drugs market is propelled by the escalating global obesity crisis and...
PR Newswire
21/06/2024
Groupe Casino: Judgment granting request by FRH and Casino for exemption of…
Judgment granting request by FRH and Casino for exemption of mandatory tender offer obligation regarding Cnova as provided in Article 5:70(1) of the Dutch Financial Supervision Act Paris, 21 June 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) hereby informs as follows: also on behalf of France Retail Holdings S.à r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH and Casino Guichard-Perrachon S.A…
Nasdaq GlobeNewswire
21/06/2024
ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia…
The objective of this guideline is to offer a comprehensive overview of evidence in making informed treatment decisions. Developed over several years, the ISTH assembled a multidisciplinary panel comprising physicians and patient representatives with global representation, balanced to mitigate potential biases. This diverse panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The objective of this guideline is to offer a comprehensive overview of...
PR Newswire
21/06/2024
Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien…
Idorsia's dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category 'Primary & Speciality'.Each year, the Prix Galien Suisse honors the most innovative new medicines and diagnostics on the Swiss market.Allschwil, Switzerland – June 21, 2024Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been...
Nasdaq GlobeNewswire
21/06/2024
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for…
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first- and best-in-class treatments to the rare blood disorders communityInterim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protectionNew ATLAS phase 3 study data reinforce the potential of fitusiran to...
Nasdaq GlobeNewswire
21/06/2024
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. OnOctober...
PR Newswire
21/06/2024
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike
The article continued: Last year, the FDA granted a total of 50 approvals for various oncology drugs. This year, the National Cancer Institute projects there will be an estimated 2,001,140 new cases of cancer diagnosed in the USA in 2024, with an expected 611,720 people projected to die from the disease. The article continued: Last year, theFDAgranted atotal of 50 approvalsfor various oncology drugs. This year, theNational Cancer Instituteprojects there will be anestimated...
PR Newswire
20/06/2024
Polycystic Ovarian Syndrome Market to Advance at Moderate CAGR During the Study…
Key Takeaways from the Polycystic Ovarian Syndrome Market Report Key Takeaways from the Polycystic Ovarian Syndrome Market Report Discover which therapies are expected to grab the major polycystic ovarian syndrome market share @Polycystic Ovarian Syndrome Market Report Polycystic Ovarian Syndrome Overview Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women, presenting a variety of signs, symptoms, and phenotypes. These can include reproductive,...
PR Newswire
20/06/2024
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for…
TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE base editors do not create break within DNA strands as does CRISPR/Cas9, or other engineered nucleases, and is a promising therapeutic strategy for genetic diseases. A key aspect to broaden the scope of possible applications is our comprehension of design rules.TALE base editors rely on the deamination of cytidines within double strand DNA, leading to the formation of an uracil (U)...
Nasdaq GlobeNewswire
20/06/2024
Altri Comunicati
